• Goldman Sachs sets a price target of $102 for NASDAQ:GPCR, indicating a potential increase of approximately 15.07%.
• Aleniglipron demonstrates a clinically meaningful weight loss of 11.3% in Phase 2b study.
• The company faces challenges from adverse events and competition from compounded drugs.

Structure Therapeutics Inc. (NASDAQ:GPCR) is a biopharmaceutical company focused on developing innovative treatments for obesity. The company is currently seeking approval for its experimental weight-loss pill, aleniglipron. This drug is an oral small molecule similar to Eli Lilly's orforglipron but with a shorter half-life. Structure Therapeutics faces competition from compounded copycat versions of weight-loss drugs, a common challenge in the obesity drug market.

On January 19, 2026, Goldman Sachs set a price target of $102 for GPCR, indicating a potential price increase of approximately 15.07% from its current price of $88.64. This optimistic outlook comes as Structure Therapeutics released promising topline data from its ACCESS clinical program. The core Phase 2b ACCESS study showed that aleniglipron achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 11.3% at the 120 mg dose over 36 weeks.

Despite the positive clinical results, the company faces challenges. There is a 10.4% adverse event-related treatment discontinuation rate across all active arms of the study. Additionally, the CEO has expressed concerns about compounded drugs posing a threat to new obesity treatments. These challenges highlight the competitive and complex nature of the obesity drug market.

Currently, GPCR is trading at $88.64, with a recent price change of $3.62, marking a 4.26% increase. The stock has fluctuated between a low of $84.71 and a high of $92.85 today. Over the past year, GPCR has reached a high of $94.90 and a low of $13.22. The company's market capitalization is approximately $5.1 billion, with a trading volume of 1,623,455 shares.